干旱区生态环境知识资源中心(Arid): Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials

Arid

DOI	10.3390/vaccines9050525
	Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials
	Dumoulin, Daphne W.; Cornelissen, Robin; Bezemer, Koen; Baart, Sara J.; Aerts, Joachim G. J. V.
通讯作者	Dumoulin, DW (corresponding author), Erasmus MC Canc Inst, Dept Pulm Med, NL-3015 GD Rotterdam, Netherlands.
来源期刊	VACCINES
EISSN	2076-393X
出版年	2021
卷号	9 期号:5
英文摘要	Background: Malignant pleural mesothelioma (MPM) is a fatal neoplasm with, if untreated, poor survival of approximately nine months from diagnosis. Until recently, phase II-III immunotherapy trials did not show any significant benefit. The lack of immunotherapy efficacy can be explained by the fact that mesothelioma is a tumor with an immune desert phenotype, meaning a non-inflamed tumor characterized by low T-cell infiltration. By administration of DCs, which were ex-vivo cultured, exposed to (tumor-associated) antigens, and subsequently activated, this immune desert phenotype might be turned into an inflamed phenotype. Three phase I/II studies have been performed and published using activated DCs, which support this concept. We here report on the long-term survival of patients treated with DCs in three phase I/II studies. Methods: Survival data of the phase I/II trials using DC therapy in MPM patients were obtained and subsequently analyzed. In the first two trials, DCs were loaded with autologous tumor lysate. In the third trial, DCs were loaded with allogeneic mesothelioma tumor cell line lysate. Results: In the three studies combined, 29 patients with MPM were treated with DC vaccination between 2006 and 2015. At data cut-off, the median OS was 27 months (95% CI: 21-47 months). OS at 2 years was 55.2% (95% CI: 39.7-76.6%), and OS at 5 years was 20.7% (95% CI: 10.1-42.2%). Conclusions: The long-term survival of DC therapy in MPM in these three trials is promising, which is the basis for the randomized phase II/III DENIM study. This DENIM study is currently enrolling, and the results of which have to be awaited for definite conclusions.
英文关键词	malignant pleural mesothelioma dendritic cells vaccination tumor lysate immunotherapy
类型	Article
语种	英语
开放获取类型	gold, Green Published
收录类别	SCI-E
WOS记录号	WOS:000654622200001
WOS关键词	MALIGNANT-PLEURAL-MESOTHELIOMA ; RANDOMIZED PHASE-III ; IMMUNOTHERAPY ; MULTICENTER ; LYSATE ; CHEMOTHERAPY ; CISPLATIN ; NIVOLUMAB
WOS类目	Immunology ; Medicine, Research & Experimental
WOS研究方向	Immunology ; Research & Experimental Medicine
资源类型	期刊论文
条目标识符	http://119.78.100.177/qdio/handle/2XILL650/351929
作者单位	[Dumoulin, Daphne W.; Cornelissen, Robin; Bezemer, Koen; Aerts, Joachim G. J. V.] Erasmus MC Canc Inst, Dept Pulm Med, NL-3015 GD Rotterdam, Netherlands; [Baart, Sara J.] Erasmus MC, Dept Biostat, NL-3015 GD Rotterdam, Netherlands
推荐引用方式 GB/T 7714	Dumoulin, Daphne W.,Cornelissen, Robin,Bezemer, Koen,et al. Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials[J],2021,9(5).
APA	Dumoulin, Daphne W.,Cornelissen, Robin,Bezemer, Koen,Baart, Sara J.,&Aerts, Joachim G. J. V..(2021).Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials.VACCINES,9(5).
MLA	Dumoulin, Daphne W.,et al."Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials".VACCINES 9.5(2021).